Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Optimal PEEP for Postoperative Oxygenation and Lung Aeration (ULTRASVENT-2) (ULTRASVENT-2)

Effect of Positive End-Expiratory Pressure (PEEP) Level on Postoperative Oxygenation and Lung Aeration Assessed by Lung Ultrasound Monitoring: A Multicenter Randomized Controlled Trial (ULTRASVENT-2)

The purpose of this multicenter, randomized controlled trial (ULTRASVENT-2) is to evaluate the effect of different positive end-expiratory pressure (PEEP) levels on postoperative oxygenation and lung aeration in adult patients undergoing elective non-cardiac and non-thoracic surgery under general anesthesia. Moving away from traditional binary outcomes, this study utilizes a continuous functional metric, the non-invasive oxygenation index SpO2/FiO2 (S/F ratio), as the primary endpoint to precisely capture the degree of respiratory function preservation.

Patients will be stratified into four distinct surgical cohorts based on the type and aggressiveness of the procedure: non-abdominal surgery, major open abdominal surgery, major laparoscopic abdominal surgery, and low-trauma laparoscopic surgery. This adaptive design aims to investigate how protective PEEP strategies interact with varying degrees of surgical trauma and intraoperative pneumoperitoneum, allowing the optimization of mechanical ventilation parameters for routine clinical practice.

Studienübersicht

Detaillierte Beschreibung

Postoperative pulmonary complications remain a significant cause of morbidity and prolonged hospital stay after major surgical interventions under general anesthesia. While positive end-expiratory pressure (PEEP) is widely used to prevent alveolar collapse, the optimal target levels across different surgical sub-types remain controversial in modern anesthesiology. This trial aims to establish robust clinical evidence regarding perioperative lung protection using a comprehensive functional-anatomical approach.

Primary Endpoint and Measurement Standardization:

The primary outcome of the trial is the non-invasive oxygenation index, the S/F ratio (SpO2/Fraction of inspired oxygen), assessed exactly 2 hours post-extubation in the Post-Anesthesia Care Unit (PACU) and tracked dynamically over the first 24 hours of the postoperative period. To eliminate confounding variables and ensure absolute reproducibility across participating centers, the primary endpoint measurement is strictly standardized according to the following criteria:

  1. Room Air Breathing (FiO2 0.21): The evaluation is performed while the patient breathes atmospheric air without supplemental oxygen. This eliminates the masking of intrapulmonary shunts and prevents hyperoxia-induced absorption atelectasis.
  2. Patient Position: The patient must be placed in a strict supine position. This positioning represents the most physiologically challenging state for the respiratory system, inducing cranial displacement of the diaphragm and maximizing gravity-dependent alveolar collapse.
  3. Full Wakefulness Criteria: The measurement is executed only when the patient reaches a full awake status, defined as a modified Post Anesthesia Recovery Score (PARS) greater than 8, with the specific ventilation sub-score being equal to 2 (ability to deep breathe and cough freely). This cognitive and motor filter guarantees that any recorded functional impairment is caused by true parenchymal collapse rather than residual neuromuscular blockade or opioid-induced respiratory depression.

Differentiated Lung Ultrasound (LUS) Track:

To identify the anatomical substrate behind changes in gas exchange, regional lung aeration patterns will be recorded as the key secondary endpoint using a delta LUS score (postoperative score minus preoperative baseline). The diagnostic burden on the investigators is optimized using two parallel diagnostic tracks:

  • Express Track (Strata 1 and 4): A rapid, 2-zone simplified protocol focusing exclusively on the most gravity-dependent bilateral dorsal-basal sectors (Zone 6). This assessment takes 2 to 3 minutes and minimizes interference with routine PACU workflows.
  • Panoramic Mapping Track (Strata 2 and 3): A comprehensive 12-zone thoracic mapping performed under Intensive Care Unit (ICU) conditions. Furthermore, a nested validation sub-study will incorporate high-resolution chest computed tomography (CT) scans performed strictly based on clinical indications (such as refractory hypoxemia or suspected pneumonia). CT data will serve as the gold standard reference to calculate the true sensitivity and specificity of the 12-zone ultrasound findings.

Surgical Stratification and Sample Size Design:

Patients will be randomized in a 1:1 ratio to receive either a fixed standard (lower) PEEP or a fixed higher PEEP strategy throughout the intraoperative period (from intubation to extubation). Randomization is performed independently within 4 parallel strata to achieve a total sample size of 320 to 360 patients:

  • Strata 1: Non-abdominal surgery (n = 100; PEEP 5 cm H2O versus PEEP 8 cm H2O).
  • Strata 2: Major open abdominal surgery (n = 60 to 80; PEEP 5 cm H2O versus PEEP 8 cm H2O).
  • Strata 3: Major laparoscopic abdominal surgery (n = 60 to 80; PEEP 7 cm H2O versus PEEP 12 cm H2O).
  • Strata 4: Low-trauma laparoscopic surgery (n = 100; PEEP 5 cm H2O versus PEEP 12 cm H2O).

Statistical Analysis Framework:

Data processing will be conducted in the jamovi software environment using General Linear Models (GLM). The analysis will incorporate continuous and categorical baseline covariates (Body Mass Index, age, ASA physical status, and duration of surgery) to reduce residual variance. A key element of the statistical plan is the evaluation of interaction effects between the PEEP level and the specific surgical stratum to determine whether a higher PEEP provides a universal benefit or if its protective role is strictly dependent on the surgical phenotype.

Implementation Protocol Phases:

To guarantee data integrity and eliminate investigator bias, the project is structured into four consecutive logical phases:

Phase 1: Regulatory start, including central registration on ClinicalTrials.gov, Local Ethics Committee (LEC) submission and approval, and prospective publication of the formal Study Protocol manuscript.

Phase 2: Standardized hands-on calibration and training of the core investigator team (4 to 6 specialists) regarding precise zone identification and digital data entry.

Phase 3: A mandatory run-in period dedicated to inter-rater reliability testing. Each investigator must scan a test cohort, and the enrollment of randomized trial patients can begin only after achieving an inter-operator consensus threshold defined as a Cohen's Kappa coefficient greater than or equal to 0.7 and an absolute category agreement greater than or equal to 80%.

Phase 4: Active enrollment utilizing an adaptive recruitment strategy. The trial will commence by enrolling patients in high-volume, low-risk groups (Strata 1 and 4) to seamlessly refine logistical and database processes before activating the complex and labor-intensive ICU-based cohorts (Strata 2 and 3).

Studientyp

Interventionell

Einschreibung (Geschätzt)

360

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Ivan Shcheparev, MD, PhD
  • Telefonnummer: +7 901 908 90 88
  • E-Mail: is22@list.ru

Studienorte

    • Moscow
      • Moscow, Moscow, Russland, 108814
        • Moscow Multi-disciplinary Clinical Center "Kommunarka"
        • Kontakt:
          • Ivan Shcheparev, MD, PhD
          • Telefonnummer: +7 901 908 90 88
          • E-Mail: is22@list.ru

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • Age greater than or equal to 18 years.
  • Planned elective non-cardiac and non-thoracic surgical intervention requiring general anesthesia with mechanical ventilation.
  • Airway protection utilizing an endotracheal tube.
  • Assignment to one of the four specific surgical strata: non-abdominal, major open abdominal, major laparoscopic abdominal, or low-trauma laparoscopic surgery.
  • Baseline lung ultrasound showing no pathological findings, corresponding to a total preoperative LUS score of 0.
  • Technical feasibility of performing a postoperative lung ultrasound within the first 2 hours after the completion of surgery.
  • Signed written informed consent to participate in the clinical trial.

Exclusion Criteria:

  • Planned cardiac or thoracic surgery (e.g., coronary artery bypass grafting, valve replacement, heart transplantation, lung resection, esophageal surgery).
  • Pneumothorax diagnosed before or during the surgical procedure.
  • Inability to adequately visualize the target dorsal-basal lung zones by ultrasound due to physical limitations (e.g., morbid obesity, massive surgical dressings, anatomical anomalies, or dermatological lesions in the scanning area).
  • Presence of hydrothorax detected on the baseline preoperative ultrasound.
  • Confirmed perioperative aspiration of gastric contents or other foreign material.
  • Any pathological changes identified during the baseline ultrasound of the dorsal-basal lung regions (a total preoperative LUS score greater than 0).
  • Requirement for massive blood transfusion during the surgery, defined according to local institutional criteria.
  • Surgical interventions directly involving or violating the diaphragm.
  • Expected inability to conduct reliable postoperative clinical and ultrasound assessments (e.g., need for deep sedation preventing wakefulness and contact, or planned transfer to another facility).

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Standard PEEP Strategy
Patients randomized to this arm will receive a fixed, standard (lower) level of Positive End-Expiratory Pressure (PEEP) throughout the intraoperative period (from intubation to extubation). The specific PEEP value is determined strictly by the surgical stratum: 5 cm H2O for Strata 1 (Non-abdominal surgery), 5 cm H2O for Strata 2 (Major open abdominal surgery), 5 cm H2O for Strata 3 (Major laparoscopic abdominal surgery), and 5 cm H2O for Strata 4 (Low-trauma laparoscopic surgery). All other mechanical ventilation parameters remain standardized (tidal volume 6-8 mL/kg of ideal body weight).
Application of fixed PEEP levels calculated according to surgical aggressiveness and the presence of pneumoperitoneum. Standard PEEP arm utilizes PEEP values of 5 cm H2O. Higher PEEP arm utilizes protective PEEP values of 8 or 12 cm H2O. The assigned PEEP strategy is initiated immediately following endotracheal intubation and maintained continuously until extubation.
Experimental: Higher PEEP Strategy
Patients randomized to this arm will receive a fixed, higher level of Positive End-Expiratory Pressure (PEEP) designed for protective lung ventilation throughout the intraoperative period. The specific PEEP value is tailored to the surgical stratum and abdominal risk: 8 cm H2O for Strata 1 (Non-abdominal surgery), 8 cm H2O for Strata 2 (Major open abdominal surgery), 12 cm H2O for Strata 3 (Major laparoscopic abdominal surgery), and 12 cm H2O for Strata 4 (Low-trauma laparoscopic surgery). All other mechanical ventilation parameters remain standardized (tidal volume 6-8 mL/kg of ideal body weight).
Application of fixed PEEP levels calculated according to surgical aggressiveness and the presence of pneumoperitoneum. Standard PEEP arm utilizes PEEP values of 5 cm H2O. Higher PEEP arm utilizes protective PEEP values of 8 or 12 cm H2O. The assigned PEEP strategy is initiated immediately following endotracheal intubation and maintained continuously until extubation.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Non-invasive oxygenation index (SpO2/FiO2 ratio)
Zeitfenster: Assessed at 3 time points: preoperatively (baseline); exactly 2 hours post-extubation; and 24 hours post-operation.

The primary functional outcome is the SpO2/FiO2 (S/F) ratio, a continuous metric indicating the degree of lung oxygenation. The S/F ratio is calculated by dividing the peripheral capillary oxygen saturation (SpO2) by the fraction of inspired oxygen (FiO2). To ensure standardization, postoperative measurements are performed on room air in a supine position. Measurements are recorded strictly when the patient achieves full wakefulness, which is verified using the modified Post Anesthesia Recovery Score (PARS) as a readiness criteria. The PARS scale ranges from a minimum of 0 to a maximum of 10, where higher scores indicate a better clinical recovery.

Note: The reported outcome is solely the S/F ratio value; the PARS score is used exclusively as a clinical condition to initiate the S/F measurement and is not aggregated into the final outcome value.

Assessed at 3 time points: preoperatively (baseline); exactly 2 hours post-extubation; and 24 hours post-operation.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of Postoperative Pulmonary Complications (PPCs)
Zeitfenster: From the end of surgery up to 7 days post-operation.
The composite clinical outcome evaluates the total percentage of patients developing at least one severe respiratory adverse event in the postoperative period. PPCs are strictly defined as the presence of one or more of the following: confirmed hospital-acquired pneumonia, prolonged requirement for supplemental oxygen therapy lasting longer than 24 hours, or the onset of refractory hypoxemia necessitating unexpected transfer to the Intensive Care Unit for non-invasive or invasive mechanical ventilation.
From the end of surgery up to 7 days post-operation.
Postoperative lung ultrasound score and aeration patterns
Zeitfenster: Exactly 2 hours post-extubation in the Post-Anesthesia Care Unit (PACU) or Intensive Care Unit (ICU).

Evaluation of the absolute postoperative Lung Ultrasound (LUS) score to assess anesthesia-induced alveolar collapse. A differentiated protocol is used based on surgical strata.

Strata 1 and 4 use a 2-zone express protocol targeting dorsal-basal sectors (total scale range: minimum 0 to maximum 6).

Strata 2 and 3 use a comprehensive 12-zone panoramic thoracic mapping protocol (total scale range: minimum 0 to maximum 36).

For both LUS scales, higher scores indicate a worse outcome (more severe loss of lung aeration and atelectasis). Specific qualitative acoustic patterns (e.g., multiple B-lines, subpleural consolidations, or static bronchograms) are also recorded to validate the numerical LUS score.

Exactly 2 hours post-extubation in the Post-Anesthesia Care Unit (PACU) or Intensive Care Unit (ICU).
Incidence of Intraoperative Hemodynamic Instability
Zeitfenster: Intraoperatively (from the moment of endotracheal intubation until extubation).
Frequency of intraoperative hemodynamic instability episodes directly related to mechanical ventilation settings, specifically measured as the requirement for the initiation or dose increase of vasopressor support (ephedrine, phenylephrine, or norepinephrine) to maintain a mean arterial pressure (MAP) greater than 65 mm Hg.
Intraoperatively (from the moment of endotracheal intubation until extubation).

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Ivan Shcheparev, MD, PhD, Moscow Multi-disciplinary Clinical Center "Kommunarka"
  • Studienleiter: Denis Protsenko, MD, PhD, Professor, Moscow Multi-disciplinary Clinical Center "Kommunarka"
  • Studienstuhl: Efim Shifman, MD, PhD, Professor, Moscow Multi-disciplinary Clinical Center "Kommunarka"

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Juli 2026

Primärer Abschluss (Geschätzt)

1. Dezember 2026

Studienabschluss (Geschätzt)

20. Dezember 2026

Studienanmeldedaten

Zuerst eingereicht

19. Mai 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

23. Mai 2026

Zuerst gepostet (Tatsächlich)

29. Mai 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

29. Mai 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

23. Mai 2026

Zuletzt verifiziert

1. Mai 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

De-identified individual participant data (IPD) that underlie the results reported in the primary publication (including baseline characteristics, intraoperative mechanical ventilation parameters, lung ultrasound scores, and clinical postoperative outcomes) will be made publicly available to ensure absolute transparency and academic reproducibility.

IPD-Sharing-Zeitrahmen

Data will become available immediately following the official publication of the primary trial results, with no specified end date.

IPD-Sharing-Zugriffskriterien

The dataset will be openly accessible to any researcher, clinician, or analyst interested in replicating the study findings, conducting systematic reviews, or performing secondary meta-analyses. The data will be hosted publicly, and no formal research proposal review or data use agreements are required for access.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • ICF
  • CSR

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Postoperative Komplikationen

Klinische Studien zur Intraoperative Positive End-Expiratory Pressure (PEEP) Regulation

Abonnieren